NCT02269592View on ClinicalTrials.gov

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

RecruitingOBSERVATIONAL
Enrollment

10,000

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2025

Study Completion Date

September 30, 2030

Conditions
Monoclonal Gammopathy of Undetermined Significance (MGUS)Chronic Lymphocytic Leukemia (CLL)Myelodysplastic SyndromesHematological MalignanciesB-cell Malignancy, Low-gradeMyelodysplastic Syndrome With Low-grade LesionsIgG Monoclonal Gammopathy of Uncertain SignificanceSmoldering Multiple MyelomaWaldenstrom Macroglobulinemia
Trial Locations (7)

49007

RECRUITING

West Michigan Cancer Center, Kalamazoo

02115

RECRUITING

Dana-Farber Cancer Institute, Boston

02135

RECRUITING

Dana Farber Cancer Institute at St. Elizabeth's, Brighton

01844

RECRUITING

Dana Farber Cancer Institute at Merrimack Valley, Methuen

01757

RECRUITING

Dana Farber Cancer Institute at Milford Regional Medical Center, Milford

02190

RECRUITING

Dana Farber Cancer Institute at South Shore, Weymouth

03053

RECRUITING

Dana Farber/New Hampshire Oncology-Hematology, Londonderry

All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

lead

Dana-Farber Cancer Institute

OTHER